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der commercial plans and PDP for 2 high-use drugs in each of the six therapeutic
classes deemedmedically necessary by CMS for beneficiaries aswell as two statins,
for reference. METHODS: TRx and OPC were collected annually from 2002 to 2009
for the two most prescribed drugs in the six medically necessary classes: anticon-
vulsants, antidepressants, oral antineoplastics, antipsychotics, immunosuppres-
sants, and HIV/AIDS—plus statins (14 drugs total). Data are from SDI’s VONA and
VOPA, analyzed with 2-way ANOVA; significance at p0.05. RESULTS: All drugs
analyzed had annual increases of10% per year in PDP prescription volume. How-
ever, nine drugs had significantly greater annual increases in commercial plan
prescription volumes before PDP than after, compared to only one with signifi-
cantly greater increases after PDP. Six drugs had significantly greater increases in
overall prescription volume after PDP compared to before. Five drugs had annual
OPC increases of at10% per year in PDP compared to two that posted at least 10%
annual decreases. Six drugs had significantly greater annual OPC increases before
PDP compared to after under commercial plans; only one had greater increases
after Part D compared to before. Five drugs showed significantly greater increases
in overall OPC (all payment forms averaged) before PDP compared to after.
CONCLUSIONS: In commercial drug plans, the advent of Part D correlates with
slower increases in drug utilization. However, Part D utilization has increased sig-
nificantly for all drugs, indicating a greater shift toward Part D plans. That only five
drugs under Part D increased in OPC bymore than 10% (and two decreased overall)
suggests that this shift may be due to greater patient access.
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OBJECTIVES: The use of multiple medications can increase the risk of adverse
effects, drug interactions and non-compliance with drug therapy, all of whichmay
result in less-than-optimal health outcomes. Seniors are at a particularly high risk
of adverse effects. Although it may be appropriate for a patient to be taking a high
number of medications, the additional risks should be considered. This analysis
examines the number and types of drugs being used by seniors, andhowutilization
changes as seniors age. METHODS: Claims level data from the National Prescrip-
tion Drug Utilization Information System (NPDUIS) Database were analyzed for
1,039,642 seniors on public drug programs in six Canadian provinces between 2002
and 2008, representing over 80% of the senior population in those provinces in
2008. Drug classes were defined using theWorld Health Organization’s Anatomical
Therapeutic Chemical classifications. The number of drugs was calculated as the
number of unique drug classes a person claimed in a given year. RESULTS: In 2008,
21.4% of seniors on public drug programs had claims for 10 or more drug classes, a
slight increase from 2002 (18.6%). The number of drug classes used by seniors
increased with age. The most commonly used drug classes were used to treat
chronic conditions such as high cholesterol, high blood pressure, heart failure, and
emphysema. 3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase inhibitors were
the most commonly used drug class among seniors aged 65 to 84, while single-
ingredient angiotensin-converting enzyme inhibitors were the most commonly
used class among those aged 85 and over. CONCLUSIONS: Findings suggest a high
proportion of seniors may be at risk for drug interactions and other adverse events
due to the number of medications they are taking. This illustrates the importance
ofmedicationmanagement strategies for seniors, and the need for communication
between health care providers regarding seniors’ drug regimens.
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OBJECTIVES:With the imminent $40 billion expansion of Medicaid in 2014, health
insurers face new opportunities to benefit by privately managing these growing
plans for some of the larger states. Overall, the States will see a 32% increase—
approximately 16 million— in Medicaid enrollees in 2014 (UnitedHealth). We ana-
lyzed the potential windfall of this expansion in the ten states with the largest
projected growth in five of the largest drug markets. METHODS: Prescription vol-
ume (TRx) and out-of-pocket costs (OPC) in five of the largest drugmarkets (depres-
sion, diabetes, hypertension, cholesterol, pain) were obtained for the ten states
with the largest Medicaid enrollment increases (California, Texas, Florida, Penn-
sylvania, Ohio, Michigan, Georgia, North Carolina, Illinois, Louisiana; Source: Unit-
edHealth). Data were obtained from June 2006 to June 2010; SDI VONA and VOPA
databases. RESULTS:Medicaid prescriptions represent a significant portion of TRx
in the 10 states analyzed, from 2.7% (MI) to 8.9% (IL). Furthermore, Medicaid ac-
counts for a considerable fraction of TRx in each of the drug markets analyzed,
from 1.5% (cholesterol) to 3.2% (pain). The average annual changes in Medicaid
prescriptions were highly variable—from7.5% (OH) to 8.2% (IL). Average national
OPC among these drug markets have decreased an average of 20.1% per year com-
pared to a decrease of 4.8% among private insurers. CONCLUSIONS: Medicaid al-
ready represents a significant portion of prescription volume, and that patient access
is constantly increasingwithprecipitouslydecreasingOPC.With the impending rise in
Medicaid enrollment in 2014, prescription volumeswill increase further, representing
a great opportunity for the external management of Medicaid plans.
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OBJECTIVES:The primary research questionwas to identify trends in cost of the six
protected medication classes in the Part D program based on plan type and low
income status between calendar years 2007 and 2008. The second research ques-
tion was to identify trends in gap phase and catastrophic phase entry.METHODS:
The primary data source was the prescription drug event data in the Chronic
Condition Warehouse (CCW) for 2007 and 2008. Data were inflation-adjusted.
Results are based on analysis of 100% data for Medicare beneficiaries in the
CCW. The six protected medication classes under study were anticonvul-
sants, antidepressants, antineoplastics, antipsychotics, antiretrovirals, and
immunosuppressants. RESULTS: Beneficiaries enrolled in PDPs had higher drug
costs per person across all drug classes for both years compared to those in MA-
PDs. LIS enrollees had higher drug costs per person for each year for the drug
classes compared to non-LIS enrolleeswith the exception of antineoplastics. These
findings were in the context of number of prescriptions filled per enrollee increas-
ing less than one percent between calendar years 2007 and 2008 for all drug classes.
Odds ratio point estimates between the two years for gap phase entry and cata-
strophic phase entry indicate that PDP and LIS enrollees were more likely to reach
the gap and catastrophic phases as compared to their counterparts (i.e., MA-PD and
non-LIS enrollees) for both calendar years. CONCLUSIONS: Findings suggest that
drug costs per person increased from 2007 to 2008. In general, the increase was
higher for MA-PD enrollees (compared to PDP enrollees) as well as for LIS enrollees
(compared to non-LIS enrollees). A higher likelihood of gap phase and catastrophic
phase entry existed for PDP enrollees (compared to MA-PD enrollees) and for LIS
enrollees (compared to non-LIS enrollees) for all classes.
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OBJECTIVES: Seniors are estimated to account for about 40% of all Canadian retail
spending on prescription drugs, and make up a significant proportion of public
drug program expenditures. This analysis examines the types of drugs accounting
for themajority of public drug programspending for seniors, and the distribution of
program spending across seniors. METHODS: This study examined claims for
1,039,642 seniors on public drug programs in six Canadian provinces (Alberta, Sas-
katchewan,Manitoba, NewBrunswick, Nova Scotia and Prince Edward Island) from
2002 to 2008, representing over 80% of the senior population in those provinces in
2008. Public drug program spending on seniors refers only to the portion of pre-
scription costs paid by the public drug program, including professional fees and
markup, where applicable. RESULTS: In 2008, the top 10 drug classes, in terms of
public drug program spending, accounted for almost half (48.3%) of all spending on
seniors in the six provinces. 3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase
inhibitors accounted for the highest proportion of drug program spending for se-
niors, while 4 of the top 10 classes were used to treat hypertension. Almost half
(45.5%) of public drug program spending was for a small group of seniors (14.7%),
where the drug programs paid $2,500 or more of their annual drug costs. Tumour
necrosis factor alpha inhibitorswere the fastest growingdrug class, in termsof spend-
ing, growing at an average annual rate of 58.4% between 2002 and 2008.
CONCLUSIONS: Findings showalmosthalf of drugprogramspending for seniors is on
a small number of drugs. This suggests that any cost saving initiatives that impact
spending on these drugs could have a significant impact on overall public drug pro-
gram spending.
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OBJECTIVES: This study determined the frequency of OTC medication use follow-
ing treatment guidelines, specifically the percentage of patient visits recorded in
the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Am-
bulatory Medical Care Survey outpatient department (NHAMCS) that included (1)
bisphosphonates with calcium, (2) divalproex or carbamazepine therapy with folic
acid, and (3) fentanyl or methadone therapy with a laxative. METHODS: A retro-
spective, observational study was conducted using NAMCS and NHAMCS data
from 2006-2008. Data for visits including bisphosphonates with calcium, dival-
proex or carbamazepine in women of childbearing age with folic acid, and metha-
done or fentanyl in adults over age 40 years with laxatives were collected. Descrip-
tive statistics and logistic regression were used to analyze weighted data to
produce national estimates. RESULTS: Calcium was used in 25.3% of visits with
bisphosphonate therapy; visits associated with antiepileptics and chronic opioids
had lower rates of supplementation, with 5.0% including folic acid and 3.7% includ-
ing laxatives. Visits by Asians (OR2.74;CI 1.42-5.27) and patients from the north-
east (OR1.57; CI 1.10-2.24) or midwest (OR1.65;CI 1.15-2.37) were more likely to
include calcium,while visits by patientswithMedicaid (OR0.48;CI 0.30-.0.78)were
least likely to include calcium. In visits with antiepileptics, Asian women (46.0%)
and women with private insurance (9.5%) were more likely to receive folic acid. In
visits that included chronic opioids, only 1.2% of patients age 40-49 years included
a laxativewhile 6.7% of visits by patients over 70 years included a laxative. Laxative
use was low in visits by African American patients (1.8%) and patients residing in a
zip code with 12.84% of the population holding a bachelor’s degree (1.9%).
CONCLUSIONS: Themajority of patients were not receiving OTC supplementation
vital to the treatment of osteoporosis, epilepsy, and chronic pain. Targeted inter-
A16 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
